CureVac Management

Management criteria checks 2/4

CureVac's CEO is Alexander Zehnder, appointed in Apr 2023, has a tenure of 1.67 years. total yearly compensation is €978.33K, comprised of 51.1% salary and 48.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $161.78K. The average tenure of the management team and the board of directors is 1.8 years and 8.8 years respectively.

Key information

Alexander Zehnder

Chief executive officer

€978.3k

Total compensation

CEO salary percentage51.1%
CEO tenure1.7yrs
CEO ownership0.03%
Management average tenure1.8yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alexander Zehnder's remuneration changed compared to CureVac's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€278m

Mar 31 2024n/an/a

-€273m

Dec 31 2023€978k€500k

-€260m

Compensation vs Market: Alexander's total compensation ($USD1.02M) is below average for companies of similar size in the UK market ($USD1.49M).

Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.


CEO

Alexander Zehnder (54 yo)

1.7yrs

Tenure

€978,331

Compensation

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...


Leadership Team

NamePositionTenureCompensationOwnership
Alexander Zehnder
CEO, MD & Member of Management Board1.7yrs€978.33k0.025%
$ 161.8k
Malte Greune
COO, Member of Management Board & MD3.4yrs€600.74k0.0038%
$ 24.5k
Myriam Mendila
Chief Scientific Officer1.9yrs€614.49k0.0021%
$ 13.6k
Ulrike Gnad-Vogt
Senior VP & Area Head of Oncology1.9yrs€284.15kno data
Axel-Sven Malkomes
CFO & Member of Executive Boardless than a yearno datano data
Thaminda Ramanayake
Chief Business Officer & Member of Executive Boardless than a yearno datano data
Sarah Fakih
Vice President Corporate Communications & Investor Relationsno datano datano data
Marco Rau
General Counselno datano datano data
Thorsten Schuller
Head of Corporate Communicationsno datano datano data
Slavica Stevanovic-Heck
Head of Human Resourcesno datano datano data
Patrick Baumhof
Senior Vice President of Technologyno datano datano data
Ronald Plasterk
Senior Vice President of Science & Innovationno datano datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: 0A9E's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Hans-Georg Rammensee
Scientific Director of Immunology and Member of Scientific Advisory Boardno datano datano data
Craig Tooman
Supervisory Board Member5.5yrs€96.25k0.0043%
$ 27.7k
Karim Fizazi
Member of Scientific Advisory Board8.8yrsno datano data
Michael Brosnan
Independent Director of Supervisory Board1.5yrs€51.03k0.0019%
$ 12.0k
Baron Stephenne
Independent Chairman of Supervisory Board9.3yrs€123.75k0.0075%
$ 48.1k
Nina Bhardwaj
Member of Scientific Advisory Board8.8yrsno datano data
Stanley Plotkin
Member of Scientific Advisory Board8.8yrsno datano data
Michael Manns
Member of Scientific Advisory Board8.8yrsno datano data
Jean-Paul Prieels
Member of Scientific Advisory Board8.8yrsno datano data
Mathias Hothum
Supervisory Board Member9.3yrs€96.25k0.0048%
$ 31.1k
Dirk Jäger
Member of Scientific Advisory Board8.8yrsno datano data
Christopher Karp
Member of Scientific Advisory Board8.8yrsno datano data

8.8yrs

Average Tenure

64yo

Average Age

Experienced Board: 0A9E's board of directors are considered experienced (8.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CureVac N.V. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlie YangBofA Global Research
Geoffrey MeachamBofA Global Research
Martin AusterCredit Suisse